Your session is about to expire
← Back to Search
Pembrolizumab for Preventing Lung Cancer
Study Summary
This trial is studying how well pembrolizumab works in preventing lung cancer in patients who have either stage I-II non-small cell lung cancer or high-risk pulmonary nodules.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have received treatment with specific medications before.I had chest radiotherapy that affected the same area as my lung nodules.I have an immune system disorder or have been on steroids recently.I am not pregnant or breastfeeding and will follow birth control advice for 120 days due to treatment risks.I need extra oxygen for my lung condition.I have lung nodules found by CT scan but no history of lung cancer.My kidney function, measured by creatinine levels or clearance, is within the required range.You have a severe allergic reaction (Grade 3 or higher) to pembrolizumab or any of its ingredients.You need to have a certain level of white blood cells in your blood.I have another cancer that is spreading or needs treatment.I am currently being treated for an infection.I have been diagnosed with HIV.I have a history of Hepatitis B or an active Hepatitis C infection.I have an active tuberculosis infection.I had early-stage lung cancer, treated it, and still have small lung nodules.Your bilirubin levels need to be within a certain range, or else you may not qualify for the study.Your AST and ALT levels in the blood should be no more than 2.5 times the upper limit of normal.Your blood clotting time is within the normal range, unless you are already taking medication to prevent blood clots and your blood clotting time is at the right level because of that medication.I have or had lung inflammation that needed steroids.I have been treated with steroids for another lung condition within the last 4 weeks.I haven't had any cancer treatment or experimental drugs in the last 4 weeks.I have not received a live vaccine in the last 30 days.I don't have any health issues that could affect the study's results.I am fully active or can carry out light work.I agree to use contraception during and after treatment for the specified times.Your hemoglobin level is at least 9.0 grams per microliter or 5.6 millimoles per liter.You have an ongoing autoimmune disease that needed strong medication in the last 2 years.A woman of childbearing potential who had a positive urine pregnancy test within 72 hours before treatment.You have at least 100,000 platelets in a small drop of blood.
- Group 1: Pembrolizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many people are eligible for this clinical study?
"That is correct. The clinicaltrials.gov website says that this research is still looking for patients to enroll. This trial was first posted on November 13th, 2018 and the listing was updated on November 8th, 2022. There are currently 81 participant openings at 2 locations."
Are researchers looking for new participants in this clinical trial at the moment?
"Yes, this trial is still recruiting patients according to the information available on clinicaltrials.gov. The listing for this study was created on November 13th, 2018 and edited for accuracy on November 8th, 2020."
What have been the most severe observed side-effects of Pembrolizumab?
"At Power, we rate the safety of Pembrolizumab as a 2. This is because, although there have been Phase 2 trials conducted which support its safety, there is currently no data to suggest that it is an effective treatment."
What are some of the most popular indications for Pembrolizumab?
"Pembrolizumab is an effective course of treatment for patients with malignant neoplasms, unresectable melanoma, and microsatellite instability high."
What are the most recent findings on Pembrolizumab?
"City of Hope first began researching pembrolizumab in 2010 and, to date, there have been 375 completed trials. At the moment, there are 1000 active studies being conducted; a significant number of these are based in New york City."
Share this study with friends
Copy Link
Messenger